A Phase 2 interventional study of VX-661 and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 36 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-04-13.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 8 in phase 2, and was the 1st registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 1 started in 2012.
This study's enrollment of 194 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 25th largest by enrollment of the 116 interventional ones that give a count, is one of 4 that started in 2012, is one of 21 in phase 2, and was the 17th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) effects of VX-661 alone and when coadministered with ivacaftor in participants with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del-CFTR mutation.
This is a Phase 2, randomized, multicenter, double-blinded, placebo-controlled, study of VX-661 monotherapy, and VX-661/ivacaftor co-therapy in participants with CF who are homozygous or heterozygous for the F508del CFTR mutation.
This study is separated into seven groups: Group 1-7, respectively. Approximately 180 participants were randomized in a ratio of 4:1; active drug to matching placebo in each group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
Drug: Placebo matched to VX-661 · Drug: Placebo matched to ivacaftor
All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
Drug: VX-661
All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
Drug: VX-661 · Drug: Placebo matched to ivacaftor
All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
Drug: VX-661 · Drug: Ivacaftor
All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
Drug: VX-661 · Drug: Placebo matched to ivacaftor
All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
Drug: VX-661 · Drug: Ivacaftor
All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
Drug: VX-661 · Drug: Ivacaftor
All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
Drug: VX-661
All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
Drug: VX-661 · Drug: Ivacaftor
All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
Drug: VX-661 · Drug: Ivacaftor
All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
Drug: VX-661 · Drug: Ivacaftor
All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
Drug: Ivacaftor · Drug: Placebo matched to VX-661
All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
Drug: VX-661 · Drug: Ivacaftor
Safety as Determined by Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the Informed Consent Form is signed. AE includes serious as well as non-serious AEs. Serious Adverse Event (SAE) is any AE that results in any of the following: death; life-threatening condition; inpatient hospitalization or prolongation of hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or other important medical event. Treatment-emergent adverse events are defined as adverse events that were reported or worsened on or after start of study drug through the Follow-up Visit (28 days after last dose of study drug) or premature discontinuation.
Time frame: Start of study drug through the Follow-up Visit (Up to Day 56)
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
Time frame: Baseline through Day 28
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
Time frame: Baseline through Day 28
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 7
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
Time frame: Baseline through Day 28
Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 1-5b
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 6
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 7
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in FEV1 (Liter [L]) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Day 7, Day 14, Day 21, Day 28
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Day 14, Day 28
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
Time frame: Baseline, Day 14, Day 28
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Baseline, Day 14, Day 28
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy
Participants who received VX-661 monotherapy (Group 1, 2a, 3a and 5a) were analyzed for this outcome measure. PK analysis (AUC0-24h) was not planned for placebo reporting arms.
Time frame: Day 28
AUC0-24h of VX-661 and AUC0-12h of Ivacaftor After Administration of VX-661 in Combination With Ivacaftor
Participants who received VX-661 in combination with Ivacaftor (Group 2b, 3b, 4, 5b, 6a, 6d and 7) were analyzed for this outcome measure. PK analysis was not planned for placebo reporting arms.
Time frame: Day 28
| Milestone | Group 1-6d Combined: Placebo | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 33 | 8 | 8 | 18 | 8 | 19 | 17 | 9 | 17 | 19 | 16 | 4 | 14 |
| Completed | 33 | 7 | 8 | 17 | 7 | 18 | 17 | 9 | 17 | 18 | 16 | 4 | 14 |
| Not completed | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the Informed Consent Form is signed. AE includes serious as well as non-serious AEs. Serious Adverse Event (SAE) is any AE that results in any of the following: death; life-threatening condition; inpatient hospitalization or prolongation of hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or other important medical event. Treatment-emergent adverse events are defined as adverse events that were reported or worsened on or after start of study drug through the Follow-up Visit (28 days after last dose of study drug) or premature discontinuation.
| participants | Group 1-6d Combined: Placebo | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with AEs | 30 | 8 | 7 | 15 | 7 | 18 | 10 | 8 | 17 | 16 | 16 | 2 | 12 |
| Participants with SAEs | 5 | 1 | 1 | 1 | 0 | 2 | 2 | 0 | 0 | 1 | 2 | 0 | 1 |
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
| millimole per liter (mmol/L) | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 1-5b Combined Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b | 3.92 (-0.5 to 8.34) | -4.76 (-9.75 to 0.22) | -5.06 (-8.02 to -2.09) | -20.43 (-24.75 to -16.12) | -6 (-8.98 to 3.02) | -6.04 (-9.12 to -2.96) | -10.46 (-14.53 to -6.39) | -2.63 (-5.67 to 0.41) | -0.86 (-3.36 to 1.65) |
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
| mmol/L | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 4 and 6 Combined: Placebo |
|---|---|---|---|
| Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6 | -6.07 (-10.84 to -1.31) | -7.89 (-12.3 to -3.48) | -1.19 (-5.5 to 3.12) |
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
| mmol/L | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|
| Change in Sweat Chloride From Baseline Through Study Day 28 for Group 7 | 10.18 (-2.48 to 22.84) | -7.02 (-14.15 to 0.11) |
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
| mmol/L | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 1-5b Combined Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Day 7 | 1.73 (-3.82 to 7.29) | -3.13 (-9.5 to 3.25) | -5.37 (-9.24 to -1.49) | -19.48 (-25 to -13.97) | -5.02 (-8.85 to -1.19) | -6.85 (-10.72 to -2.99) | -13.89 (-19.09 to -8.69) | -0.59 (-4.38 to 3.2) | 0.22 (-3.01 to 3.45) |
| Day 14 | 0.91 (-4.64 to 6.46) | -7.88 (-14.25 to -1.5) | -6.55 (-10.34 to -2.76) | -28.23 (-33.75 to 22.72) | -6.77 (-10.81 to -2.74) | -7.37 (-11.44 to -3.3) | -10.28 (-15.48 to -5.08) | -2.4 (-6.38 to 1.58) | -1.32 (-4.5 to 1.87) |
| Day 21 | 4.84 (-0.99 to 10.66) | -4.61 (-10.98 to 1.76) | -3.7 (-7.48 to 0.09) | -18.78 (-24.3 to -13.27) | -5.83 (-9.77 to -1.89) | -4.26 (-8.44 to -0.08) | -12.17 (-17.37 to -6.97) | -3.9 (-7.88 to 0.08) | -1.05 (-4.29 to 2.18) |
| Day 28 | 8.19 (2.37 to 14.02) | -3.44 (-9.82 to 2.93) | -4.62 (-8.41 to -0.83) | -15.23 (-20.75 to -9.72) | -6.37 (-10.22 to -2.52) | -5.68 (-9.76 to -1.61) | -5.5 (-10.7 to 0.3) | -3.62 (-7.6 to 0.36) | -1.27 (-4.55 to 2.01) |
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
| mmol/L | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 4 and 6 Combined: Placebo |
|---|---|---|---|
| Day 7 | -6.61 (-12.06 to -1.16) | -11.04 (-16.37 to -5.7) | -0.36 (-5.54 to 4.83) |
| Day 14 | -7.9 (-13.25 to -2.55) | -7.11 (-12.34 to -1.88) | -2.1 (-7.19 to 2.98) |
| Day 21 | -6.34 (-12 to 0.68) | -6.98 (-12.2 to -1.76) | -2.47 (-7.67 to 2.72) |
| Day 28 | -3.44 (-8.85 to 1.97) | -6.43 (-11.55 to -1.31) | 0.19 (-5.01 to 5.39) |
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.
| mmol/L | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|
| Day 7 | 4.87 (-8.32 to 18.06) | -7.28 (-14.76 to 0.2) |
| Day 14 | 10.75 (-2.44 to 23.94) | -8.95 (-16.54 to -1.35) |
| Day 21 | 9.37 (-3.82 to 22.56) | -4.14 (-11.86 to 3.58) |
| Day 28 | 15.73 (1.85 to 29.61) | -7.72 (-15.31 to -0.13) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent predicted of FEV1 | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 1-5b Combined Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Post-Baseline Through Day 28 | 3.49 (0.21 to 6.77) | 1.63 (-1.62 to 4.87) | 1.3 (-0.87 to 3.47) | 1.6 (-1.64 to 4.85) | 2.9 (0.76 to 5.03) | 3.75 (1.47 to 6.02) | 2.54 (-0.53 to 5.61) | 3.61 (1.36 to 5.86) | -0.14 (-2.02 to 1.74) |
| Day 7 | 2.72 (-1.17 to 6.62) | 0.8 (-3.09 to 4.69) | 0.47 (-2.13 to 3.06) | 3 (-0.89 to 6.89) | 2.9 (0.37 to 5.42) | 2.66 (-0.01 to 5.33) | 0.5 (-3.17 to 4.18) | 2.51 (-0.16 to 5.18) | -0.41 (-2.66 to 1.84) |
| Day 14 | 5.25 (1.35 to 9.15) | 3.72 (-0.17 to 7.61) | 0.91 (-1.69 to 3.5) | 1.61 (-2.28 to 5.5) | 1.79 (-0.78 to 4.36) | 4.52 (1.73 to 7.3) | 2.79 (-1 to 6.59) | 3.72 (1 to 6.44) | 0.03 (-2.21 to 2.28) |
| Day 21 | 2.71 (-1.34 to 6.76) | 1.8 (-2.09 to 5.69) | 1.84 (-0.75 to 4.44) | 0.25 (-3.64 to 4.15) | 3.88 (1.27 to 6.5) | 3.37 (0.58 to 6.15) | 4.52 (0.85 to 8.19) | 4.08 (1.36 to 6.8) | 0.18 (-2.07 to 2.43) |
| Day 28 | 3.26 (-0.79 to 7.32) | 0.19 (-3.7 to 4.08) | 1.99 (-0.65 to 4.63) | 1.55 (-2.34 to 5.45) | 3.02 (0.4 to 5.63) | 4.44 (1.66 to 7.23) | 2.34 (-1.33 to 6.01) | 4.13 (1.41 to 6.86) | -0.36 (-2.63 to 1.92) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
| percent predicted of FEV1 | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 4 and 6 Combined: Placebo |
|---|---|---|---|
| Post-Baseline Through Day 28 | 0.94 (-1.42 to 3.3) | 2.31 (-0.19 to 4.8) | 1.47 (-1.2 to 4.13) |
| Day 7 | 1.37 (-1.33 to 4.08) | 1.95 (-0.93 to 4.82) | 1.09 (-1.97 to 4.15) |
| Day 14 | 1.2 (-1.55 to 3.95) | 2.52 (-0.36 to 5.4) | 1.37 (-1.69 to 4.44) |
| Day 21 | 0.36 (-2.38 to 3.11) | 3.21 (0.33 to 6.08) | 1.73 (-1.39 to 4.85) |
| Day 28 | 0.81 (-1.97 to 3.6) | 1.56 (-1.32 to 4.44) | 1.67 (-1.45 to 4.8) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent predicted of FEV1 | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|
| Post-Baseline Through Day 28 | 1.4 (-5.04 to 7.83) | 4.6 (1.17 to 8.03) |
| Day 7 | 3 (-3.55 to 9.55) | 4.14 (0.65 to 7.63) |
| Day 14 | 0.98 (-5.56 to 7.53) | 5.22 (1.73 to 8.71) |
| Day 21 | 2.72 (-3.83 to 9.27) | 3.88 (0.39 to 7.38) |
| Day 28 | -1.12 (-7.66 to 5.43) | 5.16 (1.67 to 8.65) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Liters | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 1-5b Combined Placebo |
|---|---|---|---|---|---|---|---|---|---|
| PB Through Day 28 | 0.14 (0.02 to 0.26) | 0.07 (-0.05 to 0.19) | 0.05 (-0.03 to 0.13) | 0.04 (-0.08 to 0.16) | 0.1 (0.02 to 0.18) | 0.14 (0.06 to 0.23) | 0.1 (-0.01 to 0.21) | 0.12 (0.04 to 0.21) | 0.01 (-0.06 to 0.08) |
| Day 7 | 0.11 (-0.04 to 0.25) | 0.02 (-0.13 to 0.16) | 0.02 (-0.08 to 0.12) | 0.09 (-0.06 to 0.24) | 0.1 (0 to 0.19) | 0.11 (0.01 to 0.21) | 0.02 (-0.12 to 0.16) | 0.08 (-0.02 to 0.18) | -0.01 (-0.09 to 0.08) |
| Day 14 | 0.2 (0.05 to 0.34) | 0.14 (-0.01 to 0.28) | 0.03 (-0.07 to 0.12) | 0.04 (-0.11 to 0.19) | 0.05 (-0.04 to 0.15) | 0.17 (0.06 to 0.27) | 0.11 (-0.03 to 0.25) | 0.12 (0.02 to 0.23) | 0.02 (-0.07 to 0.1) |
| Day 21 | 0.12 (-0.03 to 0.27) | 0.08 (-0.06 to 0.23) | 0.07 (-0.03 to 0.17) | 0 (-0.15 to 0.15) | 0.14 (0.04 to 0.23) | 0.13 (0.02 to 0.23) | 0.18 (0.04 to 0.31) | 0.14 (0.04 to 0.24) | 0.02 (-0.06 to 0.1) |
| Day 28 | 0.13 (-0.02 to 0.28) | 0.03 (-0.11 to 0.18) | 0.08 (-0.02 to 0.18) | 0.04 (-0.11 to 0.18) | 0.1 (0.01 to 0.2) | 0.16 (0.06 to 0.27) | 0.09 (-0.05 to 0.23) | 0.15 (0.05 to 0.26) | 0.01 (-0.08 to 0.09) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
| Liters | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 4 and 6 Combined: Placebo |
|---|---|---|---|
| Post-Baseline Through Day 28 | 0.02 (-0.07 to 0.11) | 0.09 (-0.01 to 0.18) | 0.07 (-0.04 to 0.17) |
| Day 7 | 0.04 (-0.07 to 0.14) | 0.06 (-0.05 to 0.17) | 0.05 (-0.06 to 0.17) |
| Day 14 | 0.03 (-0.07 to 0.14) | 0.1 (-0.01 to 0.21) | 0.06 (-0.05 to 0.18) |
| Day 21 | -0.01 (-0.11 to 0.1) | 0.13 (0.02 to 0.24) | 0.08 (-0.04 to 0.2) |
| Day 28 | 0.02 (-0.08 to 0.13) | 0.06 (-0.05 to 0.17) | 0.08 (-0.04 to 0.2) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Liters | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|
| Post-Baseline Through Day 28 | 0.09 (-0.16 to 0.34) | 0.16 (0.03 to 0.29) |
| Day 7 | 0.14 (-0.11 to 0.39) | 0.15 (0.01 to 0.28) |
| Day 14 | 0.08 (-0.17 to 0.33) | 0.18 (0.05 to 0.32) |
| Day 21 | 0.14 (-0.11 to 0.4) | 0.13 (-0.01 to 0.26) |
| Day 28 | -0.01 (-0.26 to 0.25) | 0.19 (0.05 to 0.32) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 1-5b Combined Placebo |
|---|---|---|---|---|---|---|---|---|---|
| PB Through Day 28 | 4.02 (-4.38 to 12.43) | 5.54 (-2.72 to 13.79) | 3.8 (-1.74 to 9.35) | 0.61 (-7.64 to 8.86) | 3.52 (-2.02 to 9.06) | 5.15 (-0.88 to 11.19) | 2.58 (-5.21 to 10.37) | 7.62 (1.78 to 13.45) | 1.69 (-3.1 to 6.48) |
| Day 14 | 6.67 (-2.9 to 16.25) | 4.84 (-4.73 to 14.41) | 4.29 (-2.09 to 10.67) | 0.27 (-9.3 to 9.83) | 2.81 (-3.56 to 9.19) | 4.41 (-2.58 to 11.4) | 4.13 (-4.9 to 13.16) | 7.13 (0.37 to 13.89) | 0.53 (-4.99 to 6.05) |
| Day 28 | 1.38 (-8.7 to 11.45) | 6.23 (-3.34 to 15.8) | 3.31 (-3.21 to 9.84) | 0.95 (-8.61 to 10.52) | 4.22 (-2.29 to 10.74) | 5.9 (-1.1 to 12.89) | 1.03 (-8 to 10.06) | 8.1 (1.34 to 14.87) | 2.85 (-2.76 to 8.46) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.
| units on a scale | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 4 and 6 Combined: Placebo |
|---|---|---|---|
| Post-Baseline Through Day 28 | 0.87 (-4.44 to 6.19) | 1.91 (-3.5 to 7.33) | 1.65 (-4.18 to 7.49) |
| Day 14 | 2.02 (-3.97 to 8.02) | 0.87 (-5.25 to 6.99) | 2.78 (-3.76 to 9.32) |
| Day 28 | -0.27 (-6.27 to 5.72) | 2.96 (-3.16 to 9.08) | 0.53 (-6.18 to 7.23) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|
| Post-Baseline Through Day 28 | -3.02 (-13.52 to 7.47) | 3.79 (-1.78 to 9.36) |
| Day 14 | 1.83 (-10.64 to 14.3) | 5.24 (-1.56 to 12.04) |
| Day 28 | -7.87 (-20.34 to 4.6) | 2.33 (-4.24 to 8.91) |
Participants who received VX-661 monotherapy (Group 1, 2a, 3a and 5a) were analyzed for this outcome measure. PK analysis (AUC0-24h) was not planned for placebo reporting arms.
| nanogram*hour per milliliter (ng*hr/mL) | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 3a: VX-661 100 mg qd | Group 5a: VX-661 150 mg qd |
|---|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy | 6260 ± 2650 | 23000 ± 6550 | 88100 ± 51100 | 98900 ± 20200 |
Participants who received VX-661 in combination with Ivacaftor (Group 2b, 3b, 4, 5b, 6a, 6d and 7) were analyzed for this outcome measure. PK analysis was not planned for placebo reporting arms.
| ng*h/mL | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5b: VX-661 150 mg qd/ Ivacaftor 150 mg q12h | Group 6a: VX-661 100 mg qd/ Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/ Ivacaftor 150 mg q12h | Group 7: VX-661 100 mg qd |
|---|---|---|---|---|---|---|---|
| AUC0-24h of VX-661 | 8950 ± 2370 | 26300 ± 5870 | 82700 ± 23300 | 138000 ± 49700 | 77600 ± 17800 | 73300 ± 22900 | 90600 ± 30800 |
| AUC0-12h of Ivacaftor | 10100 ± 4380 | 11700 ± 4870 | 10900 ± 3890 | 16000 ± 10400 | 3690 ± 1460 | 11700 ± 5450 | 12400 ± 6170 |
Collected over Start of study drug through the Follow-up Visit (Up to Day 56). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1-6d Combined: Placebo | — | 5/33 (15.2%) | 30/33 (90.9%) |
| Group 1: VX-661 10 mg qd | — | 1/8 (12.5%) | 8/8 (100%) |
| Group 2a: VX-661 30 mg qd | — | 1/8 (12.5%) | 7/8 (87.5%) |
| Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | — | 1/18 (5.6%) | 15/18 (83.3%) |
| Group 3a: VX-661 100 mg qd | — | 0/8 (0%) | 7/8 (87.5%) |
| Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | — | 2/19 (10.5%) | 18/19 (94.7%) |
| Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | — | 2/17 (11.8%) | 9/17 (52.9%) |
| Group 5a: VX-661 150 mg qd | — | 0/9 (0%) | 8/9 (88.9%) |
| Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | — | 0/17 (0%) | 17/17 (100%) |
| Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | — | 1/19 (5.3%) | 16/19 (84.2%) |
| Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | — | 2/16 (12.5%) | 16/16 (100%) |
| Group 7: Placebo | — | 0/4 (0%) | 2/4 (50%) |
| Group 7: VX-661 100 mg qd | — | 1/14 (7.1%) | 12/14 (85.7%) |
| Event | Group 1-6d Combined: Placebo | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 5/33 | 1/8 | 1/8 | 1/18 | 0/8 | 1/19 | 2/17 | 0/9 | 0/17 | 1/19 | 2/16 | 0/4 | 0/14 |
| PyrexiaGeneral disorders | 0/33 | 1/8 | 0/8 | 0/18 | 0/8 | 0/19 | 0/17 | 0/9 | 0/17 | 0/19 | 0/16 | 0/4 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/33 | 1/8 | 0/8 | 0/18 | 0/8 | 0/19 | 0/17 | 0/9 | 0/17 | 0/19 | 0/16 | 0/4 | 0/14 |
| GastroenteritisInfections and infestations | 0/33 | 1/8 | 0/8 | 0/18 | 0/8 | 0/19 | 0/17 | 0/9 | 0/17 | 0/19 | 0/16 | 0/4 | 0/14 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/33 | 0/8 | 0/8 | 0/18 | 0/8 | 0/19 | 0/17 | 0/9 | 0/17 | 0/19 | 0/16 | 0/4 | 1/14 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/33 | 0/8 | 0/8 | 0/18 | 0/8 | 1/19 | 0/17 | 0/9 | 0/17 | 0/19 | 0/16 | 0/4 | 0/14 |
| Event | Group 1-6d Combined: Placebo | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 7: Placebo | Group 7: VX-661 100 mg qd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 3/33 | 4/8 | 1/8 | 1/18 | 1/8 | 3/19 | 0/17 | 1/9 | 2/17 | 0/19 | 1/16 | 0/4 | 1/14 |
| NauseaGastrointestinal disorders | 1/33 | 1/8 | 2/8 | 2/18 | 1/8 | 2/19 | 1/17 | 4/9 | 0/17 | 1/19 | 5/16 | 0/4 | 2/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/33 | 3/8 | 3/8 | 2/18 | 2/8 | 3/19 | 2/17 | 2/9 | 3/17 | 4/19 | 3/16 | 0/4 | 4/14 |
| DizzinessNervous system disorders | 0/33 | 0/8 | 3/8 | 0/18 | 0/8 | 0/19 | 0/17 | 1/9 | 0/17 | 0/19 | 1/16 | 0/4 | 0/14 |
| PyrexiaGeneral disorders | 2/33 | 2/8 | 0/8 | 0/18 | 0/8 | 1/19 | 0/17 | 1/9 | 1/17 | 1/19 | 0/16 | 0/4 | 2/14 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 2/33 | 2/8 | 2/8 | 2/18 | 1/8 | 1/19 | 2/17 | 2/9 | 1/17 | 2/19 | 3/16 | 0/4 | 0/14 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/33 | 2/8 | 0/8 | 0/18 | 2/8 | 1/19 | 1/17 | 0/9 | 1/17 | 0/19 | 1/16 | 0/4 | 1/14 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/33 | 2/8 | 0/8 | 0/18 | 1/8 | 0/19 | 0/17 | 1/9 | 1/17 | 2/19 | 1/16 | 1/4 | 1/14 |
| RalesRespiratory, thoracic and mediastinal disorders | 0/33 | 2/8 | 0/8 | 2/18 | 0/8 | 1/19 | 2/17 | 0/9 | 1/17 | 0/19 | 0/16 | 1/4 | 1/14 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 1/33 | 0/8 | 0/8 | 0/18 | 0/8 | 0/19 | 1/17 | 0/9 | 2/17 | 1/19 | 1/16 | 1/4 | 0/14 |
| Age, Continuous(years) | Group 1-6d Combined: Placebo | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 7: Placebo | Group 7: VX-661 100 mg qd | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 30.7 ± 8.42 | 35.3 ± 8.26 | 30.8 ± 6.63 | 28.3 ± 7.05 | 29.1 ± 7.12 | 29.2 ± 6.39 | 31 ± 9.3 | 28.2 ± 8.6 | 28.2 ± 6.46 | 27.9 ± 5.58 | 32.8 ± 11.92 | 34.5 ± 7.59 | 26.6 ± 7.01 | 29.8 ± 7.97 |
| Sex: Female, Male(Participants) | Group 1-6d Combined: Placebo | Group 1: VX-661 10 mg qd | Group 2a: VX-661 30 mg qd | Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h | Group 3a: VX-661 100 mg qd | Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h | Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h | Group 5a: VX-661 150 mg qd | Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h | Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h | Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h | Group 7: Placebo | Group 7: VX-661 100 mg qd | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 13 | 4 | 4 | 6 | 3 | 6 | 11 | 3 | 10 | 7 | 7 | 3 | 6 | 83 |
| Male | 20 | 4 | 4 | 12 | 5 | 13 | 6 | 6 | 7 | 12 | 9 | 1 | 8 | 107 |
The record gives a start of Feb 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 4 years 1 month after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →